Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Regeneron (REGN – Research Report) yesterday and set a price target of ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Regeneron Pharmaceuticals, Inc. (REGN) reported positive results from the Phase 3 C-POST trial, which showed that adjuvant treatment ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported positive results from the Phase 3 C-POST trial, which showed that adjuvant treatment with PD-1 inhibitor Libtayo led to a statistically ...

According to InvestingPro analysis, Regeneron maintains strong financial health with robust cash flows and minimal debt exposure. The C-POST study involved 415 patients who were randomized to receive ...

These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects ...